News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Eledon Pharmaceuticals’ (Nasdaq: ELDN) Up to $185 Million Private PlacementMay 2023
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Assertio (NASDAQ: ASRT) on its Pending Acquisition of Spectrum (NASDAQ: SPPI) in an All-Stock and CVR TransactionApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to Human API on its Sale to LexisNexis Risk Solutions, a part of RELX (NYSE: RELX)April 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Applied Therapeutics’ (Nasdaq: APLT) $30.0 Million Private PlacementApril 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Vaxcyte’s (Nasdaq: PCVX) $500 Million Follow-On OfferingApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor to MedStream Anesthesia on Its Sale to National Partners in HealthcareApril 2023
News | Deal AnnouncementSVB Securities Serves as Lead Placement Agent for Regulus Therapeutics’ (Nasdaq: RGLS) $15.0 Million Private PlacementApril 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Harpoon Therapeutics’ (Nasdaq: HARP) $25 Million Private PlacementMarch 2023
News | Deal AnnouncementSVB Securities Serves as Exclusive Financial Advisor for Wellvana’s $84 Million Capital RaiseMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for 89bio’s (Nasdaq:ETNB) Upsized $275 Million Follow-On OfferingMarch 2023
News | NewsSVB Securities Sets Record Straight on the Current and Previous Role of Chief Administrative Officer Joseph GentileMarch 2023
News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Stagwell’s (NASDAQ: STGW) $108 Million Follow-On OfferingMarch 2023